This variant is located in a hepatocyte-specific open chromatin region and establishes an enhancer-promoter (E-P) interaction with the promoter of APOA5, which is a known activator of LPL activity and closely linked to MASLD progression52. Here, APOA5 is linked to metabolic dysfunction-associated steatotic liver disease.